The company’s expansion into new market segments and continued racing success signal confidence in the long-term strength of ...

The commercial motorcycle rider who was swept away by flood in Ekpoma, Esan West Local Government Area, on Tuesday, has been confirmed dead. DAILY POST reports that the lifeless body of the deceased, ...

AbbVie has reached settlements with all generic drugmakers to resolve litigation that challenged their plans to introduce generics of its arthritis drug Rinvoq, per an MSN report. The generic drug ...

A yet-to-be-identified commercial motorcycle rider and a student were on Tuesday, reportedly swept away by flood in Ekpoma, Esan West Local Government Area of Edo State. DAILY POST reports that the ...

AbbVie has bolstered the sales outlook of its blockbuster autoimmune drug Rinvoq (upadacitinib) by extending its exclusivity until 2037. The company accomplished the feat via settlements with generics ...

Sept 11 (Reuters) - AbbVie shares rose 4% to a record high on Thursday after the U.S. drugmaker said it expected no generic competition for its blockbuster immunology drug Rinvoq until 2037, a ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. AbbVie announced this morning it has settled litigation ...

AbbVie has struck a deal with generic drugmakers aimed at extending patent protection for its blockbuster autoimmune drug Rinvoq well into the next decade. AbbVie on Thursday said it has settled ...

AbbVie has struck a deal with generic drugmakers aimed at extending patent protection for its blockbuster autoimmune drug Rinvoq by more than a decade. AbbVie on Thursday said it has settled ...

AbbVie ABBV-0.68%decrease; red down pointing triangle has struck a deal with generic drugmakers aimed at extending patent protection for its blockbuster autoimmune drug Rinvoq well into the next ...

MONTREAL, Aug. 27, 2025 /CNW/ - AbbVie today announced that Health Canada has issued a Notice of Compliance for RINVOQ ® (upadacitinib) for the treatment of adults with giant cell arteritis (GCA), ...

RINVOQ is the first and only oral advanced therapy approved for the treatment of giant cell arteritis (GCA) in Canadian adults 1 GCA is the most common vasculitis in Canada, primarily affecting adults ...